Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on uniQure. The associated price target remains the same with $110.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Patrick Trucchio has given his Buy rating due to a combination of factors, primarily focusing on the promising clinical data and the unmet medical need in Huntington’s disease (HD). Despite recent feedback from the FDA introducing some uncertainty regarding the approval pathway for AMT-130, Trucchio remains optimistic about the potential for a viable regulatory path in the U.S. due to the robust data generated so far.
The 3-year results from uniQure’s Phase 1/2 trials demonstrate significant potential for AMT-130 to modify disease progression in HD, a condition with no approved disease-modifying treatments. The therapy has shown a substantial slowing of disease progression and favorable safety outcomes, which supports its potential as a groundbreaking treatment. Additionally, recent FDA draft guidances suggest flexibility in trial designs, which may ultimately benefit AMT-130’s approval process. These factors collectively underpin Trucchio’s confidence in maintaining a Buy rating for uniQure’s stock.
Trucchio covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Aligos Therapeutics, and Arrowhead Pharmaceuticals. According to TipRanks, Trucchio has an average return of 34.8% and a 52.26% success rate on recommended stocks.